Allergy Therapeutics (AGY) — Tangible Net Worth Ratio
Allergy Therapeutics (AGY) has a Tangible Net Worth Ratio of 63.1% as of June 2024. This metric is calculated by deducting intangible assets (GBX1.37 Million) from net assets (GBX3.71 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Allergy Therapeutics (AGY) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Allergy Therapeutics Tangible Net Worth Ratio (2003–2024)
This chart shows how Allergy Therapeutics's Tangible Net Worth Ratio has changed across 20 annual periods from 2003 to 2024. As of June 2024, the ratio stands at 63.1%, reflecting net assets of GBX3.71 Million with intangible assets of GBX1.37 Million GBX. See AGY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Allergy Therapeutics (2003–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Allergy Therapeutics from 2003 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market cap of Allergy Therapeutics.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 63.1% | GBX3.71 Million | GBX1.37 Million | GBX64.83 Million | ▲ +176.0 pp |
| 2023 | -113.0% | GBX2.07 Million | GBX4.40 Million | GBX66.77 Million | ▼ -199.6 pp |
| 2022 | 86.7% | GBX37.77 Million | GBX5.04 Million | GBX72.95 Million | ▼ -3.5 pp |
| 2021 | 90.2% | GBX48.53 Million | GBX4.75 Million | GBX88.09 Million | ▲ +1.0 pp |
| 2020 | 89.2% | GBX43.78 Million | GBX4.74 Million | GBX86.22 Million | ▼ -7.1 pp |
| 2019 | 96.3% | GBX37.56 Million | GBX1.41 Million | GBX68.50 Million | ▲ +2.9 pp |
| 2018 | 93.3% | GBX23.03 Million | GBX1.54 Million | GBX51.02 Million | ▲ +0.2 pp |
| 2017 | 93.1% | GBX29.96 Million | GBX2.07 Million | GBX57.18 Million | ▼ 0.0 pp |
| 2016 | 93.1% | GBX30.32 Million | GBX2.08 Million | GBX56.68 Million | ▼ -1.0 pp |
| 2015 | 94.1% | GBX34.47 Million | GBX2.02 Million | GBX50.70 Million | ▲ +2.7 pp |
| 2014 | 91.4% | GBX15.07 Million | GBX1.29 Million | GBX28.40 Million | ▲ +0.6 pp |
| 2013 | 90.8% | GBX14.67 Million | GBX1.35 Million | GBX28.96 Million | ▲ +5.2 pp |
| 2012 | 85.6% | GBX14.59 Million | GBX2.11 Million | GBX27.75 Million | ▲ +68.8 pp |
| 2011 | 16.7% | GBX2.14 Million | GBX1.78 Million | GBX30.62 Million | ▼ -61.1 pp |
| 2010 | 77.9% | GBX3.89 Million | GBX860.00K | GBX29.11 Million | ▼ -8.6 pp |
| 2007 | 86.5% | GBX8.60 Million | GBX1.16 Million | GBX23.99 Million | ▼ -19.1 pp |
| 2006 | 105.6% | GBX32.70 Million | GBX-1.82 Million | GBX37.88 Million | ▲ +10.3 pp |
| 2005 | 95.3% | GBX20.08 Million | GBX951.00K | GBX26.66 Million | ▲ +52.0 pp |
| 2004 | 43.2% | GBX7.08 Million | GBX4.02 Million | GBX11.23 Million | ▲ +23.1 pp |
| 2003 | 20.1% | GBX5.55 Million | GBX4.43 Million | GBX11.15 Million | — |